home / lobbying

lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

217 rows where filing_period = "second_quarter", filing_year = 2015 and issue_code = "PHA" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: filing_type, is_termination, received_date (date)

issue_code 1

  • PHA · 217 ✖

filing_year 1

  • 2015 · 217 ✖

filing_period 1

  • second_quarter · 217 ✖
id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
1688499 MR. THEODORE (TED) JONES 8302036a-ef2c-4bb9-bce3-8a027980df1d 2T MR. THEODORE (TED) JONES 20926 COQUI RADIOPHARMACEUTICALS, CORP. 2015 second_quarter PHA American Medical Isotopes Production Act of 2012 that was contained in the National Defense Authorization Act for Fiscal Year 2013. Acceleration of production of 99 MO using LEU (Low Enriched Uranium). HOUSE OF REPRESENTATIVES,SENATE 10000   0 1 2015-04-30T16:46:06.453000-04:00
1689568 ANGELA STEWART 841047b9-c46b-4a4b-8500-dcfa61a3e62c 2T ANGELA STEWART 401103673 EISAI, INC 2015 second_quarter PHA DEA scheduling of controlled substances Improving Regulatory Transparency for New Medical Therapies Act (H.R. 639/S. 481) HOUSE OF REPRESENTATIVES,SENATE 30000   0 1 2015-06-11T16:00:20.950000-04:00
1690015 AMERICAN COLLEGE OF CLINICAL PHARMACY ec950903-d25c-4842-b331-7073538a2f11 Q2 AMERICAN COLLEGE OF CLINICAL PHARMACY 57258 AMERICAN COLLEGE OF CLINICAL PHARMACY 2015 second_quarter PHA Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   127250 0 0 2015-07-01T10:51:59.033000-04:00
1691489 HANCE SCARBOROUGH e7150692-a139-44b1-aec5-cfbacd8252d2 Q2 HANCE SCARBOROUGH 17443 ALLIANCE OF INDEPENDENT PHARMACISTS - TEXAS 2015 second_quarter PHA Federal legislation affecting the practice of pharmacy, and FDA and DEA regulations of compounded drugs. HOUSE OF REPRESENTATIVES,SENATE     0 0 2015-07-08T12:29:50.343000-04:00
1691604 KATE MOSS ffca5642-33de-4577-a5dc-0130934dd430 Q2 KATE MOSS 25988 CVS HEALTH 2015 second_quarter PHA Issues related to prescription drug abuse and drug supply chain safety. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2015-07-08T14:17:17.637000-04:00
1691690 BLUECROSS BLUESHIELD OF TENNESSEE 32122152-27ca-47ed-8882-c9b6b73190e7 Q2 BLUECROSS BLUESHIELD OF TENNESSEE 6440 BLUECROSS BLUESHIELD OF TENNESSEE 2015 second_quarter PHA General Pharmacy Issues; specialty drug pricing Equal Employment Opportunity Commission (EEOC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   30000 0 0 2015-07-08T15:36:07.090000-04:00
1691787 CONNECT 4 STRATEGIES, LLC d4713c88-0bde-4d90-b103-e1691e41c09c 2A CONNECT 4 STRATEGIES, LLC 401103720 OREXO US, INC. 2015 second_quarter PHA S2645 & HR2536 Recovery Enhancement for Addiction Treatment Act - Patient Caps Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2015-07-08T19:06:11.097000-04:00
1692002 THORSEN FRENCH ADVOCACY LLC 3c1f1fba-f7ad-4527-81db-af7b7e0322f0 Q2 THORSEN FRENCH ADVOCACY LLC 400599826 ASTRAZENECA PHARMACEUTICALS LP 2015 second_quarter PHA Issues related to access to pharmaceuticals. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2015-07-09T12:58:51.687000-04:00
1692158 WAXMAN STRATEGIES 0c08c6f5-210f-49e2-b5f6-180f656515a8 Q2 WAXMAN STRATEGIES 401103693 340B HEALTH 2015 second_quarter PHA Laws and regulations affecting the 340B Drug Discount Program Health & Human Services, Dept of (HHS) 12500   0 0 2015-07-09T14:43:30.980000-04:00
1692358 ACG ADVOCACY 49807e2e-0982-4da7-abd2-d31a06ef7de1 Q2 ACG ADVOCACY 2057 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2015 second_quarter PHA Advocacy on Medicare and Medicaid pharmacy coverage and reimbursement issues. Advocating for coverage of pharmacists services under Medicare Part B. Advocating for the passage of legislation that curbs prescription drug abuse while protecting patient access to medication. Advocating for fair and accurate Medicaid pharmacy reimbursement. Advocating for Medicare Part D changes that increase beneficiary eligibility for medication therapy management. Issues related to pharmacy reimbursement for 21st Century Cures. Issues regarding TriCare coverage for pharmacies. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2015-07-09T17:53:56.627000-04:00
1692460 OMNICARE, INC. 3664d5c8-e22e-4d54-9c2c-1df3527ee676 Q2 OMNICARE, INC. 321112 OMNICARE INC 2015 second_quarter PHA Drug Enforcement Administration rule on disposal of controlled substances in long term care facilities; Reclassification of hydrocodone-containing prescription drugs from Schedule III to Schedule II drugs; Controlled substances policy; Biosimilars policy; Hazardous drug handling policy; FDA drug compounding policy     20000 0 0 2015-07-10T09:16:38.803000-04:00
1692597 VALENTE & ASSOCIATES d0d8e7b5-570b-424e-916b-bfdfe211882b Q2 VALENTE & ASSOCIATES 45983 SAV-MOR FRANCHISING, INC. 2015 second_quarter PHA Medicare Part D HOUSE OF REPRESENTATIVES     0 0 2015-07-10T11:17:27.037000-04:00
1692650 NELSON MULLINS RILEY & SCARBOROUGH c2f6a2da-380a-42e2-9ae6-8b96461201d1 Q2 NELSON MULLINS RILEY & SCARBOROUGH 285871 INDIVIOR (FORMERLY, RECKITT BENCKISER PHARMACEUTICALS, INC.) 2015 second_quarter PHA Any legislation and regulation to the treatment of opioid abuse. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2015-07-10T11:48:06.790000-04:00
1692716 INDEPENDENT PHARMACY COOPERATIVE 09d4859c-3508-48c3-9d63-0977bb86f1f3 Q2 INDEPENDENT PHARMACY COOPERATIVE 313098 INDEPENDENT PHARMACY COOPERATIVE 2015 second_quarter PHA H.R. 592/S.314 Pharmacy and Medically Underserved Areas Enhancement Act. IPC is supportive of pharmacists being recognized as providers under Medicare Part B for these areas. H.R. 793 Ensuring Seniors Access to Local Pharmacies Act. IPC is support of local pharmacies being able to participate in Medicare Part D in these underserved areas. HR 6 21st Century Cures Act. IPC is not supportive of some of the "pay for" provisions. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE     0 0 2015-07-10T12:59:58.017000-04:00
1692754 UNIVERSITY OF IOWA c151004d-ae6a-4713-985d-840ffb837a53 Q2 UNIVERSITY OF IOWA 49191 UNIVERSITY OF IOWA 2015 second_quarter PHA Increased appropriations for systems to shorten the time between development of a drug and its release to the public FDA reform as it relates to drug development and research Collaborative research on drug development Human factors research related to neuropharmaceuticals Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Federal Emergency Management Agency (FEMA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Transportation, Dept of (DOT)   86662 0 0 2015-07-10T13:15:35.480000-04:00
1693309 THE D MAJOR GROUP 9a33130a-6d63-463d-88e7-a3646b62f863 Q2 THE D MAJOR GROUP 401103162 CVS CAREMARK 2015 second_quarter PHA Issues related to innovation in pharmacy delivery, including health information technology. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2015-07-13T00:09:39.470000-04:00
1693407 RED+BLUE STRATEGIES e923f7b9-52d8-4dde-94d4-95b07f8b08f6 Q2 RED+BLUE STRATEGIES 400693064 EXPRESS SCRIPTS INC. 2015 second_quarter PHA H.R.6 - 21st Century Cures - Issues related to exclusivity rights of certain prescription medications. Rules, regulations, guidance and potential legislation specific to prescription drug pricing, generic utilization, biosimilars medications and specialty pharmacy. Issues related to the treatment of pharmacy benefit managers in federal programs. Policies related to stopping the diversion of prescription medications in the nation's drug supply chain. Issues related to access and affordability for prescription medications for both government and private sector benefit programs. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2015-07-13T11:00:02.040000-04:00
1693413 PD FRAZER CONSULTING, INC. 2f55f1c7-3f62-4cb1-b293-021c6dcb07a3 Q2 PD FRAZER CONSULTING, INC. 65998 CANADA INTERNATIONAL PHARMACY ASSOCIATION 2015 second_quarter PHA Monitor the development of proposed bills about the importation of prescription drugs. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2015-07-13T11:02:07.510000-04:00
1693776 NELSON MULLINS RILEY & SCARBOROUGH 08e5931a-01b5-4369-8f51-e74e19b17936 Q2 NELSON MULLINS RILEY & SCARBOROUGH 285871 CASCADE HEMOPHILIA CONSORTIUM 2015 second_quarter PHA Issues related to 340B Drug Pricing Progam HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2015-07-13T14:55:00.397000-04:00
1693784 NELSON MULLINS RILEY & SCARBOROUGH 728bf530-6ae6-4b58-bc4a-f489c7ee6572 Q2 NELSON MULLINS RILEY & SCARBOROUGH 285871 HEMOPHILIA OF GEORGIA 2015 second_quarter PHA Issues related to implementation of the ACA, Hemophilia research and treatments, and the 340B Drug Pricing Program HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2015-07-13T14:57:07.177000-04:00
1693792 ROCK & ASSOCIATES fed95fb7-02bc-43a3-8206-5fcb7410a5c5 Q2 ROCK & ASSOCIATES 33545 BRAIDWOOD MANAGEMENT, INC. 2015 second_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2015-07-13T15:14:14.787000-04:00
1693810 ROCK & ASSOCIATES f2cd0269-700f-433f-9216-c488321a1cca Q2 ROCK & ASSOCIATES 33545 DIAMONDBACK DRUGS 2015 second_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2015-07-13T15:30:25.540000-04:00
1693837 ROCK & ASSOCIATES aaf1d6cf-1dc0-4c43-bcc8-32a97df0c0df Q2 ROCK & ASSOCIATES 33545 TOWN & COUNTRY COMPOUNDING AND CONSULTING 2015 second_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. No specific legislation yet. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2015-07-13T15:42:38.853000-04:00
1693843 ROCK & ASSOCIATES f8b0723d-9a63-4385-b4ae-a26c2b95f56d Q2 ROCK & ASSOCIATES 33545 US COMPOUNDING 2015 second_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2015-07-13T15:48:44.887000-04:00
1693855 ROCK & ASSOCIATES 03d9485a-7e2f-4dd5-9851-9faa6828a292 Q2 ROCK & ASSOCIATES 33545 VETERINARY PHARMACIES OF AMERICA, INC. 2015 second_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2015-07-13T15:53:53.013000-04:00
1693863 ROCK & ASSOCIATES 441a13ac-a166-47c1-ba31-00c4cb4318f7 Q2 ROCK & ASSOCIATES 33545 WEDGEWOOD VILLAGE PHARMACY, INC. 2015 second_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2015-07-13T15:56:57.700000-04:00
1693874 ROCK & ASSOCIATES e7a539ab-489b-49d6-825f-ef15a0927764 Q2 ROCK & ASSOCIATES 33545 WOMEN'S INTERNATIONAL PHARMACY 2015 second_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2015-07-13T16:03:06.513000-04:00
1693947 MR. GALEN RESER 014a1b58-40dc-4315-9099-65a206120724 Q2 MR. GALEN RESER 401055978 PERRIGO INC (THROUGH FTI GOVERNMENT AFFAIRS) 2015 second_quarter PHA Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines, "Restoring Access to Medication Act of 2015," H.R. 1270, S. 709. FDA's proposed changes to generic drug labeling. House Energy and Commerce 21st Century Cures Initiative. Senate Health, Education, Labor and Pensions 21st Century Cures Initiative. "Fairness to Pet Owners Act of 2015," S.1200. HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2015-07-13T16:50:06.033000-04:00
1693950 GARY BUEHLER 53c42e80-b24c-4e6d-b737-70b8b1306145 Q2 GARY BUEHLER 401103724 TEVA PHARMACEUTICALS USA, INC. 2015 second_quarter PHA Section 505(b)(2) new drug applications and exclusivity period. HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2015-07-13T16:52:07.160000-04:00
1693989 ROCK & ASSOCIATES dee85a42-1c88-4030-afa9-bb8b94501637 Q2 ROCK & ASSOCIATES 33545 WELLNESS PHARMACY 2015 second_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 11250   0 0 2015-07-13T17:18:28.807000-04:00
1694006 RED+BLUE STRATEGIES b3ac72e8-0e2d-47ae-82e6-bc696e805d67 Q2 RED+BLUE STRATEGIES 400693064 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2015 second_quarter PHA H.R. 6 - 21st Century Cures- Issues related to opioid abuse, prescription medication exclusivity and biosimilars. Issues related to Senate Finance Committee activity on advances in chronic care with a focus on medication-based therapies. CCIIO issuer letter and regulations focused on bids for 2015 and impacts on access to prescription medications and pharmacy networks. Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks. Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits. CMS call letter focused on changes in policies regarding mail order and pharmacy networks. Issues related to pricing and access to prescription drugs including specialty drugs and biosimilars. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2015-07-13T17:27:38.167000-04:00
1694017 RED+BLUE STRATEGIES 8e0e580b-75f2-4db8-bace-275be8b74881 Q2 RED+BLUE STRATEGIES 400693064 PEW CHARITABLE TRUSTS 2015 second_quarter PHA H.R. 6 - 21st Century Cures Act - Issues related to ensuring that medically needed antibiotics are available to the public, curbing opioid abuse in Medicare Part D and maintaining the integrity of the federal Open Payments program. S. 1549 - The Care Planning Act - supporting advances in End-of-Life Care throughout the nation. Support of the inclusion of Advanced Care Planning codes in the CMS Physician Fee Schedule (PFS). S. 633 - The Promise for antibiotics and Therapeutics for Health (PATH) Act - Focused on ensuring that the Food and Drug Administration has the necessary to tools to ensure that medically needed antibiotics are made available to the public. Issues related to ending prescription drug abuse and diversion in Medicare and Medicaid. Advancing provisions to highlight Antibiotic Innovation in the President's FY 2016 budget. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2015-07-13T17:41:44.433000-04:00
1694080 COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE d89d4372-76b5-466b-a30e-7dad40a6c9d1 Q2 COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE 11003 COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE 2015 second_quarter PHA S. 1190, Ensuring Seniors Access to Local Pharmacies Act of 2015, and H.R. 244, MAC Transparency Act HOUSE OF REPRESENTATIVES,SENATE   70000 0 0 2015-07-14T08:36:39.487000-04:00
1694794 BROWN RUDNICK LLP 67e765e3-8745-4f8a-8648-a50552a6311e Q2 BROWN RUDNICK LLP 287895 APOTEX CORPORATION 2015 second_quarter PHA Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94) HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2015-07-14T14:37:49.993000-04:00
1694822 BROWN RUDNICK LLP 51bf2334-dcca-4389-addc-a7788261dfb2 Q2 BROWN RUDNICK LLP 287895 HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC 2015 second_quarter PHA Issues relating to Implementation of P.L. 113 - 54 (Drug Quality and Security Act); H.R. 471 & S. 483 -Ensuring Patient Access and Effective Drug Enforcement Act; S. 480, H.R. 1725-relating to Prescription Drug Monitoring Programs; S. 524 & H.R. 953 relating to prescription drug abuse HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2015-07-14T14:42:04.417000-04:00
1694924 BROWN RUDNICK LLP 64457dd9-c5fd-4ec4-903c-f1592963219c Q2 BROWN RUDNICK LLP 287895 HOSPIRA, INC. 2015 second_quarter PHA Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94) HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2015-07-14T14:57:14.323000-04:00
1694935 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION f35c7d44-1c74-4ff1-9e94-337f36e598db Q2 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 29403 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2015 second_quarter PHA Pseudoephedrine Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient, common in popular cold and allergy medications (no bill number) and oppose prescription requirement (no bill number). Oral Contraceptives - S. 1438 - Allowing Greater Access to Safe and Effective Contraception Act. Grants priority review of applications to switch oral contraceptive drugs from prescription to nonprescription (over-the-counter) status; all sections S. 1532 - Affordability is Access Act. Clarifies that all oral contraceptive products be covered by insurance and provided to consumers without cost, regardless of prescription/nonprescription (over-the-counter) status; all sections. Over-the-counter (OTC) medicines; Manufacturing and importation of OTC drugs; Mandatory recall authority of the FDA; Rx-to-OTC Switch Supporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of   250000 0 0 2015-07-14T14:57:16.697000-04:00
1694951 BROWN RUDNICK LLP 17baf227-31eb-4d40-8ee0-3de6661638cd Q2 BROWN RUDNICK LLP 287895 PRIME THERAPEUTICS 2015 second_quarter PHA HR 793 - Ensuring Seniors Access to Local Pharmacies Act Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2015-07-14T15:01:26.323000-04:00
1694975 BROWN RUDNICK LLP 1e01578b-9db5-44d9-ba7d-a45c7801b700 Q2 BROWN RUDNICK LLP 287895 AMNEAL PHARMACEUTICALS 2015 second_quarter PHA Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94) HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2015-07-14T15:07:47.183000-04:00
1694981 BROWN RUDNICK LLP 29c22a5e-6220-47ab-9489-48cfebbd34e3 Q2 BROWN RUDNICK LLP 287895 EXELA HOLDINGS, LLC 2015 second_quarter PHA Issues relating to ANDA review and approval Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2015-07-14T15:09:51.700000-04:00
1694997 BROWN RUDNICK LLP dd89968a-396f-4574-b84d-20833d349b38 Q2 BROWN RUDNICK LLP 287895 ZYDUS PHARMACEUTICALS USA INC. 2015 second_quarter PHA Issues relating to generic drug pricing HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2015-07-14T15:12:59.747000-04:00
1695484 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 593c20f9-1e4c-411a-8fe2-5d6f71b14087 Q2 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 35968 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 2015 second_quarter PHA Implementation of the radiopharmaceutical provisions of The Drug Quality and Security Act as it relates to compounding. Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Energy, Dept of,Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Nuclear Regulatory Commission (NRC),Office of Science & Technology Policy (OSTP),SENATE   90000 0 0 2015-07-15T09:29:24.027000-04:00
1695541 RED+BLUE STRATEGIES e808101c-573c-432f-bc23-182080f3ca8b Q2 RED+BLUE STRATEGIES 400693064 BLUE CROSS BLUE SHIELD OF MASSACHUSETTS 2015 second_quarter PHA H.R. 6 - 21st Century Cures - Issues related to supporting programs to prevent opioid abuse in the Part D program. Issues related to opioid abuse. Issues related to state-based marketplaces. Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2015-07-15T10:04:02.030000-04:00
1695733 MERCURY PUBLIC AFFAIRS, LLC 0a5b29e9-c64a-47b8-b579-a43d9bf6bff2 Q2 MERCURY PUBLIC AFFAIRS, LLC 70175 KALISPELL REGIONAL HEALTHCARE 2015 second_quarter PHA Veteran pharmacy issues and polices Federal Communications Commission (FCC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) 30000   0 0 2015-07-15T11:00:39.943000-04:00
1695921 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. d95adbca-5e3d-4089-bbf3-cf004cb5766d Q2 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 THE HEMOPHILIA ALLIANCE 2015 second_quarter PHA issues related to the 340B drug discount program; HR 6, 21st Century Cures potential amendment Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2015-07-15T11:32:15.807000-04:00
1695934 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 3f9cc7ac-eb4f-4619-8fe8-c29bd768bb49 Q2 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 AMERICAN SOCIETY OF HEMATOLOGY 2015 second_quarter PHA HR 1600, Patient Access to Treatment Act; HR 2739 Cancer Drug Coverage Parity Act/S. 1566 Cancer Drug Coverage Parity Act Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 30000   0 0 2015-07-15T11:35:20.463000-04:00
1695941 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 88c62fd0-447d-4409-8a40-23af07142e05 Q2 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 NATIONAL HEMOPHILIA FOUNDATION 2015 second_quarter PHA Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program. HR 1600, Patients Access to Treatment Act Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE 50000   0 0 2015-07-15T11:36:25.073000-04:00
1695953 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. c37d8758-9586-45b1-bd9c-b6bbad1f62f2 Q2 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 NATIONAL ASSOCIATION OF EPILEPSY CENTERS 2015 second_quarter PHA Issues related to anti-epileptic drugs. Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 10000   0 0 2015-07-15T11:38:28.777000-04:00
1695960 CAPITOL HILL CONSULTING GROUP 01cbecaa-70e4-4cd2-9401-29b3f7cea1ac Q2 CAPITOL HILL CONSULTING GROUP 72053 ENDO PHARMACEUTICALS 2015 second_quarter PHA Issues related to tamper resistant formulation of pharmaceutical drugs; Ensuring Safe Access to Prescription Medication Act of 2014 S. 2825 HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2015-07-15T11:38:31.073000-04:00
1696238 MR. VINCENT A. PANVINI 55cc1a64-ba3a-462f-b5a0-dc25530dd0c4 Q2 MR. VINCENT A. PANVINI 401008845 PHRMA 2015 second_quarter PHA Trans-Pacific Partnership Patent Reform HOUSE OF REPRESENTATIVES,SENATE     0 0 2015-07-15T12:48:29.260000-04:00
1696922 CAPITOL HILL CONSULTING GROUP 3bdb087b-ea66-4ce8-81f5-f72da3f75f8c Q2 CAPITOL HILL CONSULTING GROUP 72053 PROFESSIONAL COMPOUNDING CENTERS OF AMERICA 2015 second_quarter PHA Issues related to PL 113-54, The Drug Quality and Security Act Issues related to agriculture appropriations and defense appropriations. Issues related to S. 1406 - saving access to compound medications for special needs patients act. Defense, Dept of (DOD),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2015-07-15T14:49:02.103000-04:00
1696929 PARRY, ROMANI, DECONCINI & SYMMS 235df27d-9564-4fce-8a2d-35da97e40e9b Q2 PARRY, ROMANI, DECONCINI & SYMMS 30792 ROCK & ASSOCIATES 2015 second_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. S.1406-Saving Access to Compounded Medications for Special Needs Patients Act. HOUSE OF REPRESENTATIVES,SENATE 7500   0 0 2015-07-15T14:50:04.667000-04:00
1696945 CAPITOL HILL CONSULTING GROUP da1a0a3f-8de7-4366-8ecf-8502d30664f1 Q2 CAPITOL HILL CONSULTING GROUP 72053 PURDUE PHARMA LLP 2015 second_quarter PHA Controlled Drug Substances Act (21 USC 13) Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2015-07-15T14:55:15.383000-04:00
1697000 RED+BLUE STRATEGIES d95b5879-0f17-4a51-a4c7-9d9d17fee602 Q2 RED+BLUE STRATEGIES 400693064 HOSPIRA 2015 second_quarter PHA Issues related to the naming of biosimilars as they enter into the national prescription drug marketplace. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2015-07-15T15:03:39.887000-04:00
1697067 THE MATHIS HARPLE GROUP 3588c434-b712-46ba-a894-c3d4677fff52 Q2 THE MATHIS HARPLE GROUP 322911 PILMA 2015 second_quarter PHA Patent Protection; 12 Year Data Exclusivity; HR 9 Innovation Act HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2015-07-15T15:14:24.387000-04:00
1697108 CHRISTY ELLERBEE CONSULTING, LLC b25c4b1a-c4c0-4229-a2c8-4a7aa169a2a2 Q2 CHRISTY ELLERBEE CONSULTING, LLC 401103332 INDIVIOR, PLC (FKA RECKITT BENCKISER PHARMACEUTICALS, INC.) 2015 second_quarter PHA Pharmaceutical issues relevant to Indivior, PLC; S. 1455 TREAT Act. HOUSE OF REPRESENTATIVES,SENATE     0 0 2015-07-15T15:20:49.887000-04:00
1697420 FTI GOVERNMENT AFFAIRS a5607d4a-068e-406b-8ebd-868ddaf753a6 Q2 FTI GOVERNMENT AFFAIRS 401054971 PERRIGO, INC. 2015 second_quarter PHA Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines, "Restoring Access to Medication Act of 2015," H.R. 1270, S. 709. FDA's proposed changes to generic drug labeling. House Energy and Commerce 21st Century Cures Initiative. Senate Health, Education, Labor and Pensions 21st Century Cures Initiative. "Fairness to Pet Owners Act of 2015," S.1200. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2015-07-15T16:34:26.770000-04:00
1697605 ACADEMY OF MANAGED CARE PHARMACY decc05c8-ba97-481b-88e5-52efc71dad86 Q2 ACADEMY OF MANAGED CARE PHARMACY 48793 ACADEMY OF MANAGED CARE PHARMACY 2015 second_quarter PHA Biosimilar naming - supporting Congressional action to seek FDA decision on naming and supporting FTC study of effect of naming on competition, Medicare Part D lock in and Medicare Part D issues concerning managed care pharmacy Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE   262000 0 0 2015-07-15T17:28:42.340000-04:00
1697754 EMPIRE CONSULTING GROUP 75507192-c6ba-42f1-8245-cb00237509f0 Q2 EMPIRE CONSULTING GROUP 400703105 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2015 second_quarter PHA Medicare Prescription Drug Act; HR 9, Innovation Act; HR 2005/S. 1083, Medicare Drug Savings Act; 340B Drug pricing program; 21st Century Cures; S.320, Medical Innovation Act; and Independent Payment Advisory Board (IPAB) repeal. HOUSE OF REPRESENTATIVES 40000   0 0 2015-07-15T19:46:18.450000-04:00
1697966 ASSOCIATION OF NATIONAL ADVERTISERS, INC. 76932127-eb90-4b74-9ba4-535cca6c2d9c Q2 ASSOCIATION OF NATIONAL ADVERTISERS, INC. 4653 ASSOCIATION OF NATIONAL ADVERTISERS, INC. 2015 second_quarter PHA Proposals relating to the regulation of direct to consumer prescription drug advertising HOUSE OF REPRESENTATIVES,SENATE   430000 0 0 2015-07-16T09:27:50.010000-04:00
1697975 WILLIAMS AND JENSEN, PLLC d1725bba-82b6-4021-ad69-c982184aa5e2 Q2 WILLIAMS AND JENSEN, PLLC 41454 FAGRON NORTH AMERICA 2015 second_quarter PHA Issues related to Drug Quality and Security Act (DQSA) and Pharmacy compounding. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2015-07-16T09:29:52.450000-04:00
1698091 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) d59e79c6-d25b-45c2-914d-a023eba1cdc7 Q2 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 28776 HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) 2015 second_quarter PHA Rx Pedigree (Public Law 113-54); Prescription Drug Monitoring Programs (S. 480, H.R. 1725); Prescription Drug Abuse - General issues related to Rx drug abuse, (H.R. 471, S. 483,S. 524, H.R. 953); Counterfeit Drugs;21st Century Cures (H.R. 6); Importation of Prescription Drugs (S. 122, H.R. 2228) Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   301000 0 0 2015-07-16T10:12:58.597000-04:00
1698686 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS c1b2a1ef-5ce4-4188-a878-f16916d8b336 Q2 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 3457 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 2015 second_quarter PHA Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. Contact concerning the Drug Quality and Security Act, all titles. Communication with the FDA on Generic Drug User Fee Act and electronic drug information. Contact with DEA regarding electronic and prescribing of controlled substances. Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   250000 0 0 2015-07-16T11:48:53.590000-04:00
1698947 RUBICON ADVISORS, LLC 1cdd06bf-611b-41d5-8c62-aacf50fb55b6 Q2 RUBICON ADVISORS, LLC 315091 TEVA PHARMACEUTICALS USA 2015 second_quarter PHA 21st Century Cures Act HOUSE OF REPRESENTATIVES,SENATE 105000   0 0 2015-07-16T12:50:29.067000-04:00
1698963 RUBICON ADVISORS, LLC 48940f4b-9e74-421b-b250-1ea5e0f4c930 Q2 RUBICON ADVISORS, LLC 315091 OFFICE OF GOVERNOR NATHAN DEAL 2015 second_quarter PHA Pharmaceuticals HR 707, Restoration of America's Wire Act HOUSE OF REPRESENTATIVES,SENATE 43750   0 0 2015-07-16T12:56:38.693000-04:00
1698967 RUBICON ADVISORS, LLC 85135abb-aefe-4162-a816-8a36df41e007 Q2 RUBICON ADVISORS, LLC 315091 DYNAVAX TECHNOLOGIES 2015 second_quarter PHA Food and Drug Administration - Vaccines Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2015-07-16T12:58:42.943000-04:00
1698980 RUBICON ADVISORS, LLC 2da08d80-cb7a-4ca6-a8ec-50badaa74b4f Q2 RUBICON ADVISORS, LLC 315091 STATE MUTUAL INSURANCE COMPANY 2015 second_quarter PHA 21st Century Cares Act HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2015-07-16T12:58:46.317000-04:00
1698982 RUBICON ADVISORS, LLC a4c06c8f-cc48-40d6-84e2-01154173a22a Q2 RUBICON ADVISORS, LLC 315091 ALLIANCE TO PREVENT THE ABUSE OF MEDICINES 2015 second_quarter PHA Prescription drug abuse policy HOUSE OF REPRESENTATIVES,SENATE 52500   0 0 2015-07-16T13:00:47.317000-04:00
1698984 RUBICON ADVISORS, LLC f58b7a9d-7042-43bd-a705-b5c8d5bd2d0e Q2 RUBICON ADVISORS, LLC 315091 COLLEGE OF AMERICAN PATHOLOGISTS 2015 second_quarter PHA Physician Payment Rates, Electronic Health Records Incentives program HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2015-07-16T13:00:51.507000-04:00
1698989 RUBICON ADVISORS, LLC 5a680884-3584-41dc-ab03-1b3ac3c14156 Q2 RUBICON ADVISORS, LLC 315091 DR. REDDY'S LABORATORIES, LTD 2015 second_quarter PHA Food and Drug Administration, Generic Drug User Fees HOUSE OF REPRESENTATIVES,SENATE 36000   0 0 2015-07-16T13:02:52.833000-04:00
1698995 RUBICON ADVISORS, LLC 03a3eca4-c6db-4d79-98c2-517173d8f008 Q2 RUBICON ADVISORS, LLC 315091 CIPLA USA, INC. 2015 second_quarter PHA Food and Drug Administration, Generic Drug User Fees HOUSE OF REPRESENTATIVES,SENATE 45000   0 0 2015-07-16T13:03:55.380000-04:00
1699179 MASON CONSULTING, LLC 1e8e74c7-8942-4656-89d6-f0449fe1fd84 Q2 MASON CONSULTING, LLC 400660986 NATIONAL ASSOCIATION OF PEDIATRIC NURSE PRACTITIONERS 2015 second_quarter PHA Legislation and policies relating to: H.R. 471/S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act H.R. 639 - Improving Regulatory Transparency for New Medical Therapies Act S. 1392 - Safe Prescribing of Controlled Substances Act Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,Veterans Affairs, Dept of (VA),White House Office 23450   0 0 2015-07-16T13:39:53.887000-04:00
1699240 MASSACHUSETTS MEDICAL SOCIETY c8e7047c-22e3-40c2-b288-ff098be2b3e4 Q2 MASSACHUSETTS MEDICAL SOCIETY 23975 MASSACHUSETTS MEDICAL SOCIETY 2015 second_quarter PHA S 320 - Medical Innovation Act - NIH funding Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE   60000 0 0 2015-07-16T13:53:26.230000-04:00
1699255 POWERS PYLES SUTTER & VERVILLE, P.C. 8577f14f-e6af-496e-b254-8b64e46e3ccd Q2 POWERS PYLES SUTTER & VERVILLE, P.C. 32008 340B HEALTH 2015 second_quarter PHA Section 340B of the Public Health Services Act, Section 1927 of the Social Security Act and issues related to (1) administration and Congressional oversight of the 340B Drug Discount Program, (2) implementation of 340B-related provisions in the Patient Protection and Affordable Care Act of 2010, and (3) funding of the Health Resources and Services Administration (HRSA)under the Labor Health & Human Services & Education appropriations bills. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2015-07-16T13:55:37.323000-04:00
1699290 AARP 1bbc659e-1ce7-4200-ad33-9439813cd62c Q2 AARP 1694 AARP 2015 second_quarter PHA H.R.6, Discussed the House Energy and Commerce Committee 21st Century Cures Initiative and Senate HELP Committee efforts focused on drug and medical device innovation issues. Discussed the importance of potential savings to both consumers and the federal government of granting Secretarial negotiating authority to the HHS Secretary under Medicare Part D. (no bill #) Discussed legislation to address pay-for-delay agreements used by drug manufacturers to block lower cost drugs from entering the market. Discussed the exclusivity period for biologic drugs. (no bill #) Discussed biologic drug issues including implementation of the new approval pathway for biosimilar drugs. Discussed other prescription drug issues and potential legislation on drug importation and least costly alternative payment for Part B drugs. (no bill #) Discussed the need for data transparency on prescription drug prices and comparativeness effectiveness research. S. 1137/Hr.9, Discussed patent reform legislation (S. 1137, the PATENT Act and H.R. 9, Innovation Act) and related provisions on the Patent and Trademark Office inter partes review (IPR) process and proposed exemptions for brand name drug patents. Discussed pending negotiations on the Trans Pacific Partnership (TPP) trade agreement and intellectual property chapter provisions on pharmaceuticals. Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Equal Employment Opportunity Commission (EEOC),Federal Communications Commission (FCC),Federal Transit Administration (FTA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),Securities & Exchange Commission (SEC),SENATE,Social Security Administration (SSA),Transportation, Dept of (DOT),Treasury, Dept of,U.S. Trade Representative (USTR),Veterans Affairs, Dept of (VA),White House Office   1889000 0 0 2015-07-16T14:01:51.060000-04:00
1699352 KOUNTOUPES DENHAM CARR & REID, LLC 30e6914b-3d9d-4bd2-b4d6-c589a6aad74b Q2 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2015 second_quarter PHA General issues related to over the counter pharmaceuticals, potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient common in popular cold and allergy medications, and opposition to prescription requirements. Issues related to "21st Century Cures" as well as FDA and NIH modernization. Draft legislation regarding microbeads in over the counter products; Issues related to the over the counter drug monograph process; Dietary Supplement amendment to the NDAA bill and H.R. 6, 21st Century Cures Act. HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of 50000   0 0 2015-07-16T14:14:29.827000-04:00
1699456 JOHNS HOPKINS UNIVERSITY 399ddb3a-ec14-4696-a248-08c02c39776b Q2 JOHNS HOPKINS UNIVERSITY 20664 JOHNS HOPKINS UNIVERSITY 2015 second_quarter PHA Pharmaceutical drug price increases; 340B drug discount program Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE   120000 0 0 2015-07-16T14:28:32.657000-04:00
1699691 HORIZON BLUE CROSS BLUE SHIELD OF NEW JERSEY 5adcf695-758b-413c-93da-9717b51597b4 Q2 HORIZON BLUE CROSS BLUE SHIELD OF NEW JERSEY 72793 HORIZON BLUE CROSS BLUE SHIELD OF NEW JERSEY 2015 second_quarter PHA 21st Century Cures HR 6 21st Century Cures Act Introduced May 19, 2015 by Fred Upton (R-MI) This bill amends the Public Health Service Act to reauthorize the National Institutes of Health (NIH) through FY2018. The NIH Innovation Fund is established to fund a strategic plan, early stage investigators, and high-risk, high-reward research. The NIH may require scientific data to be shared if the research is fully funded by the NIH. The NIH and the Food and Drug Administration (FDA) must implement a system that allows further research on clinical trial data. The Centers for Disease Control and Prevention must expand surveillance of neurological diseases. The Council for 21st Century Cures is established to accelerate the discovery, development, and delivery of innovative cures, treatments, and preventive measures. The Department of Health and Human Services must monitor the use of antibacterial and antifungal drugs and resistance to these drugs HOUSE OF REPRESENTATIVES,SENATE   30000 0 0 2015-07-16T14:55:36.207000-04:00
1700133 TARPLIN, DOWNS & YOUNG, LLC 0e9ee6bc-8739-45dc-b904-57f3d205f8fd Q2 TARPLIN, DOWNS & YOUNG, LLC 304736 HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) 2015 second_quarter PHA Importation of prescription drugs (S. 122, H.R. 2228) Rx Pedigree (PL 113-54) Prescription Drug Monitoring Programs (S. 480, H.R. 1725) Counterfeit Drugs Prescription Drug Abuse - General issues related to Rx drug abuse (H.R. 471, S. 483, S. 524, H.R. 953) 21st Century Cures (H.R. 6) Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2015-07-16T15:56:53.220000-04:00
1700367 AMERICAN HEALTH CARE ASSOCIATION f049a889-2022-43a6-9133-bfa1caf6b5b7 Q2 AMERICAN HEALTH CARE ASSOCIATION 2491 AMERICAN HEALTH CARE ASSOCIATION 2015 second_quarter PHA S. 621: Safe Prescribing Act of 2013 - continued monitoring of hydrocodone changes. Continued monitoring of Nurse Agent Continued monitoring of drug disposal issues Continued monitoring of action on antipsychotic reduction efforts. H.R. 3392 Medicare Part D patient Safety & Drug Abuse Prevention Act of 2013 Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Housing & Urban Development, Dept of (HUD),SENATE,Veterans Affairs, Dept of (VA)   960000 0 0 2015-07-16T16:32:10.600000-04:00
1700519 NOVO NORDISK INC. 4afedc04-a98f-42f9-ba29-bc439937a722 Q2 NOVO NORDISK INC. 284790 NOVO NORDISK INC. 2015 second_quarter PHA P.L. 113-54 Drug Quality and Security Act (track and trace supply chain provisions); issues regarding biosimilars; issues regarding 340B; H.R.6 21st Century Cures Act; FDA in HR 3049 FY16 Agriculture Appropriations Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE   450000 0 0 2015-07-16T17:07:04.650000-04:00
1700665 TEVA PHARMACEUTICALS USA, INC. b4c5ca4f-5826-4c1e-9a70-0505edb3633f Q2 TEVA PHARMACEUTICALS USA, INC. 76695 TEVA PHARMACEUTICALS USA INC 2015 second_quarter PHA Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,U.S. Trade Representative (USTR)   980000 0 0 2015-07-16T17:35:58.500000-04:00
1700698 FTI GOVERNMENT AFFAIRS f7fdf4a4-efbc-423c-877d-3ccf6b971168 Q2 FTI GOVERNMENT AFFAIRS 401054971 PROFESSIONAL COMPOUNDING CENTERS OF AMERICA 2015 second_quarter PHA Implementation of The Drug Quality and Security Act, H.R.3204 (Public Law). HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2015-07-16T17:44:25.767000-04:00
1700927 ISEMAN & ASSOCIATES LLC 104c71de-8054-49f3-bfc9-e8d75e147308 Q2 ISEMAN & ASSOCIATES LLC 401103582 TICHENOR VENTURES, LLC 2015 second_quarter PHA Monitoring biotech legislation HOUSE OF REPRESENTATIVES,SENATE     0 0 2015-07-16T20:12:34.957000-04:00
1700996 THE INGRAM GROUP LLC 2be467c6-a7e0-400c-9553-a3b74936f90a Q2 THE INGRAM GROUP LLC 400577737 ELI LILLY AND COMPANY 2015 second_quarter PHA General issues related to the biopharmaceutical and pharmaceutical industries. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2015-07-16T22:16:35.703000-04:00
1701372 GREATER NEW YORK HOSPITAL ASSOCIATION 85301e90-5f8f-43e1-8706-cba3977a8611 Q2 GREATER NEW YORK HOSPITAL ASSOCIATION 16830 GREATER NEW YORK HOSPITAL ASSOCIATION 2015 second_quarter PHA Reducing the costs of pharmaceuticals, medical devices, and supplies for consumers and health care providers, including implementation of the Drug Quality and Security Act (P.L.113-54) and P.L.112-144; support medical device pricing transparency and prohibition on medical device price "gag clauses"; preserving access to group purchasing organizations (GPOs) and protecting the GPO safe harbor; educating policymakers on hospital drug shortages and significant drug price increases; pharmaceutical labeling of generic drugs (FDA-2013-N-0500); legislation to create a comprehensive Medicare home infusion benefit (H.R.605/S.275) - support; support reforming the durable medical equipment competitive bidding program; supporting "any willing pharmacy" legislation; promoting access to biosimilars (labeling/interchangeability); 21st Century Cures Act (H.R.6) - general support for overall bill, support final pharmacy lock-in policy, oppose PPSA weakening of existing requirements, oppose Section 4004 treatment of infusion drugs furnished through durable medical equipment; Ensuring Seniors Access to Local Pharmacies Act (H.R.793/S.1190) - support; Pharmacy and Medically Underserved Areas Enhancement Act (S.314) - support; MAC Transparency Act (H.R.244) - support; Medication Therapy Management Empowerment Act (S.776) - support; Strengthening Medicare Advantage Through Innovation and Transparency for Seniors - oppose; FDA-2014-D-1524 - comments on draft guidance on repackaging of certain human drug products by pharmacies and outsourcing facilities; FDA-2014-N-1459 - comments on draft MOU addressing certain distributions of compounded human drug products between states and the FDA; proposed changes to the 340B prescription drug program - oppose Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office   330000 0 0 2015-07-17T08:44:38.867000-04:00
1701447 ALKERMES, INC. 60c506a3-e009-4c87-8a17-102e3582d2bf Q2 ALKERMES, INC. 400458235 ALKERMES, INC. 2015 second_quarter PHA Ensure regulatory certainty for clinical trials and subsequent scheduling of FDA-approved medicines deemed to be controlled substances. HR 639/S 481, Improving Regulatory Transparency Act for New Medical Therapies Act Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institute on Alcohol Abuse & Alcoholism (NIAA),Natl Institutes of Health (NIH),Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)   1332200 0 0 2015-07-17T09:07:14.383000-04:00
1701948 BLUESTONE STRATEGIES, LLC 6303531d-adc5-46a5-b494-60c60610e521 Q2 BLUESTONE STRATEGIES, LLC 400658980 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2015 second_quarter PHA Pharmacy Act; Generic Brand Settlement; Generic Dispensing; Generic Biologics; Specialty Drug Issues and HR 6, the 21st Century Cures Act. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2015-07-17T10:17:30.557000-04:00
1702037 BLUESTONE STRATEGIES, LLC d6f9a23f-5547-4c8a-b61f-acd2402745b2 Q2 BLUESTONE STRATEGIES, LLC 400658980 AMERICA'S HEALTH INSURANCE PLANS (AHIP) 2015 second_quarter PHA Specialty Drug Issues HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2015-07-17T10:28:14.247000-04:00
1702099 AVENUE SOLUTIONS c5e2fb19-8417-471f-bf4e-3e48302dc32c Q2 AVENUE SOLUTIONS 72111 RICHIE'S SPECIALTY PHARMACY 2015 second_quarter PHA discussions on compounding issues; TRICARE coverage of compounded medications prepared from bulk chemicals at Department of Defense, Veterans Affairs and TRICARE SENATE 60000   0 0 2015-07-17T10:37:51.310000-04:00
1702157 SANOFI US SERVICES INC. e22ee034-5531-4396-9e1f-1252286d4086 Q2 SANOFI US SERVICES INC. 56838 SANOFI US SERVICES INC 2015 second_quarter PHA General issues related to the 340B Federal Drug Pricing Program HOUSE OF REPRESENTATIVES,SENATE   510000 0 0 2015-07-17T10:43:19.263000-04:00
1702475 THE SIMMONS & RUSSELL GROUP, LLC f87bf16c-157e-4e4f-9d96-4546cb31fbf0 Q2 THE SIMMONS & RUSSELL GROUP, LLC 401103235 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) 2015 second_quarter PHA Drug importation and the FAIR Generics legislation; An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025, S.CON.RES.11. SENATE 60000   0 0 2015-07-17T11:20:15.767000-04:00
1702638 AMERICAN FEDERATION OF STATE, COUNTY AND MUNICIPAL EMPLOYEES d750cabc-59c6-4dae-9ad6-526e1428a457 Q2 AMERICAN FEDERATION OF STATE, COUNTY AND MUNICIPAL EMPLOYEES 2321 AMERICAN FEDERATION OF STATE COUNTY AND MUNICIPAL EMPLOYEES 2015 second_quarter PHA HR 2005, S 1083- Medicare Drug Savings Act HR 6- 21st Century Cures Act- especially patent lengthening provision HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Natl Labor Relations Board (NLRB),SENATE,Treasury, Dept of,U.S. Trade Representative (USTR),White House Office   690000 0 0 2015-07-17T11:41:35.833000-04:00
1702677 CAPITOL STRATEGIES GROUP, LLC 753d8685-df70-47f8-a5c7-8c04cad15986 Q2 CAPITOL STRATEGIES GROUP, LLC 400462294 PHRMA (ON BEHALF OF WE WORK FOR HEALTH ) 2015 second_quarter PHA Medical innovation HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2015-07-17T11:47:55.380000-04:00
1702978 TARPLIN, DOWNS & YOUNG, LLC 6a9537c3-768d-4ecf-8dd7-5410a8e33f04 Q2 TARPLIN, DOWNS & YOUNG, LLC 304736 ASTRAZENECA 2015 second_quarter PHA PL 112-144 - The Food and Drug Administration Safety and Innovation Act, implementation H.R. 3204 - The Drug Quality and Security Act, implementation H.R. 6 - 21st Century Cures ***, no specific bill(s), Import Safety, Prescription Drug User Fee Act renewal, drug development policy, drug shortages, supply chain integrity, patent settlements, user fee sequester relief, Innovation Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2015-07-17T12:28:51.793000-04:00
1703039 APOTEX CORP. 208f33c0-5822-4bdb-b65e-0c57cbbfc5da Q2 APOTEX CORP. 310973 APOTEX CORP. 2015 second_quarter PHA HR 6 - The 21st Century Cures Act, provisions relating to the discovery, approval and manufacturing of pharmaceuticals; FDA proposed rule, Supplemental Applications Proposing Labeling Changes For Approved Drugs And Biological Products, Docket Number FDA-2013-N-0500, provisions relating to generic drug labeling changes; HR 2841 - The FAST Generics Act of 2015, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing; S 1137 - The FAIR Generics Act, provisions relating to market blockages caused by "parked" 180 day exclusivity periods; Federal policy relating to International Nonproprietary Names for biosimilars; Federal policy relating to the implementation of the Biologic Price Competition and Innovation Act, Title VII, Subtitle A, of Public Law 111-148, The Patient Protection and Affordable Care Act; and Federal policy relating to the Implementation of Public Law 112-144, The Food and Drug Administration Safety and Innovation Act, provisions in Title 3, Fees Relating to Generic Drugs. HOUSE OF REPRESENTATIVES,SENATE   260000 0 0 2015-07-17T12:44:33.497000-04:00
1703317 AMERICAN PHARMACISTS ASSOCIATION a7cdf0c5-2e71-4bf2-b92b-7ec42844da98 Q2 AMERICAN PHARMACISTS ASSOCIATION 3071 AMERICAN PHARMACISTS ASSOCIATION 2015 second_quarter PHA Reimbursement of pharmacist services - HR592/S314 Transitions of care Risk evaluation and mitigation services Track and trace/supply chain Health information technology Immunizations Compounding Tele-medicine Quality rating AMP FULs Biosimiliars Drug importation Generics labeling Preferred pharmacy network - HR793 Electronic labeling Home infusion - HR605/S275 21st century cures Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)   27243 0 0 2015-07-17T13:33:26.517000-04:00
1703459 THE STRATEGY GROUP, INC. 1038386d-7d4c-4189-86dc-1c238fe4190a Q2 THE STRATEGY GROUP, INC. 401103637 PHRMA 2015 second_quarter PHA 340B Pharmacy Program. HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2015-07-17T13:49:45.287000-04:00
1703777 SANOFI US SERVICES INC. 6e721e25-833f-4eee-81e0-a3c50a35a9e3 2A SANOFI US SERVICES INC. 56838 SANOFI US SERVICES INC 2015 second_quarter PHA General issues related to the 340B Federal Drug Pricing Program HOUSE OF REPRESENTATIVES,SENATE   840000 0 0 2015-07-17T14:30:18.917000-04:00
1703821 TARPLIN, DOWNS & YOUNG, LLC 56a31d4f-59f3-401f-9440-a045dd3c9165 Q2 TARPLIN, DOWNS & YOUNG, LLC 304736 PHRMA 2015 second_quarter PHA PL 112-144 - The Food and Drug Administration Safety and Innovation Act, implementation H.R. 3204 - The Drug Quality and Security Act, implementation H.R. 6 - 21st Century Cures ***, no specific bill(s), prescription drug importation, import safety, supply chain integrity, Prescription Drug User Fee Act and associated policies, user fee sequester, innovation Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2015-07-17T14:33:45.760000-04:00

Next page

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            income_amount INTEGER,
            expense_amount INTEGER,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);
Powered by Datasette · Queries took 1981.476ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API